Trump's pharmaceutical investments surge amid Medicare exemptions

Merck: Merck is a pharmaceutical company known for producing Keytruda, a cancer treatment subject to the orphan drug exclusion under Medicare policy. Its stock appears in the disclosed holdings tied to the recent legislative changes discussed in the report. AbbVie: AbbVie is a pharmaceutical company that develops and markets medications, including those potentially impacted by Medicare drug pricing rules. The news references purchases of its stock for President Trump's portfolio shortly after legislation expanding exemptions took effect. Donald Trump: Donald Trump is the President of the United States, overseeing an administration that has pursued healthcare policies including deals with pharmaceutical companies aimed at affordability. In the current news, his independently managed investment portfolio holds stakes in drugmakers that gained from Republican-backed Medicare exemptions for certain medications. The White House maintains there are no conflicts of interest as neither he nor family members direct investment decisions. Democratic Party: The Democratic Party serves as the primary opposition to the Republican administration in Congress, with its members on the Joint Economic Committee issuing reports scrutinizing executive branch financial holdings. In this news, Democrats highlight perceived benefits to the president's portfolio from policy changes affecting drug pricing and pledge to reverse measures that raised costs for Medicare recipients. Sen. Maggie Hassan has described the findings as typical of an administration prioritizing personal gains. Bristol Myers Squibb: Bristol Myers Squibb is a pharmaceutical company that manufactures Opdivo, another cancer drug affected by the expanded Medicare exemptions. The news links its inclusion in the investment portfolio to the policy shielding such medications from price negotiations. Policy Impact: The orphan drug exclusion under a Republican-backed law allows certain medications to avoid Medicare price negotiations, enabling higher charges for treatments of rare diseases. Public Opinion: Recent polling shows most Americans view the president as profiting from the office in ways they consider unethical or illegal. Healthcare Approach: The Trump administration has struck deals with pharmaceutical companies to address drug affordability, even as broader policy changes expanded exemptions from negotiations.